Clinical trial · Observational
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
NCT04241367CI-TRIAL-00107727completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Adenocarcinoma | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Clinical applicability of KRAS mutations
- timeFrame
- Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
- description
- Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
- measure
- Discovery of biomarkers through ctDNA panel
- timeFrame
- Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
- description
- Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically confirmed pancreatic adenocarcinoma. Exclusion Criteria: * Patients disagree with the study.
References
Publications (1)
- DERIVEDChun JW, Lee DE, Kim MK, Hwang JH, Lee SH, Jung MK, Kim EJ, Ahn DW, Kim YH, Han SS, Park SJ, Lee WJ, Woo SM, Kong SY. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study. Clin Chem. 2025 Sep 3;71(9):993-1004. doi: 10.1093/clinchem/hvaf066. PMID 40509918